ライフサイエンスコーパス: low-density

1 populations are reduced and maintained at a low density.

2 ing season, all fish can hold territories at low density.

3 ms when the target antigen is expressed at a low density.

4 re likely to reverse adaptations attained at low densities.

5 while the energy-averaged mass saturates at low densities.

6 es-specific and predicted to be effective at low densities.

7 espondingly high stress (up to 1.3 MPa) with low density (0.84 g cm(-3)).

8 In monolayer graphene at low densities, a nonmonotonic variation of the resistanc

9 Water exists in high- and low-density amorphous ice forms (HDA and LDA), which cou

10 with high diffusion rates are likely to have low densities and be effective conduits for movement.

11 ynamically driven to rearrange in regions of low density and bond orientational order.

12 preparations of stem cell colonies seeded at low density and imaged with varying overlap (10 to 50%).

13 detected in caterpillar guts were unusually low-density and variable among individuals.

14 isadvantages of hydrogen gas arises from its low density, and therefore, efficient handling and stora

15 ial screening was conducted using the TaqMan Low Density Array followed by RT-qPCR confirmation.

16 in) in vivo and ex vivo, whilst qPCR, Taqman low-density array and immunoblot analysis of these tissu

17 A TaqMan PCR low-density array card approach revealed the abundance o

18 ected and microbiota were analyzed using Gut Low-Density Array quantitative polymerase chain reaction

19 tain empty spaces, suggesting formation in a low-density (atmospheric) environment.

20 erges due to proliferation resembles that of low-density cells treated with a combination of IL-6/8.

21 D, blood pressure, body mass index (BMI) and low-density cholesterol lipoprotein (LDL) between the tw

22 ons which suggest that in these conditions a Low Density Collisionless Shock Acceleration (LDCSA) mec

23 enriched in the histone variant H2AX, and a low-density core containing foci of phosphorylated H2AX

24 We show a very low-density, deep-seated upwelling that ascends beneath

25 se they focus on data describing early time, low-density dynamics only.

26 mponent slows down after transition into the low-density form at 130 K, but remains diffusive.

27 he diffusive character of both the high- and low-density forms is discussed among different interpret

28 ulent reservoirs of cool (about 100 kelvin), low-density gas, extending far (more than 10 kiloparsecs

29 d only in very dense gas, and is absorbed in low-density gas.

30 th and without sepsis and CD14(neg)CD15(pos) low-density granulocytes/granulocytic (G)-MDSCs were mor

31 ehaved, regardless of ligand density, like a low density, high affinity ligand in all these parameter

32 es are ubiquitous in nature because of their low-density, high-specific properties, and multifunction

33 ions within the host material and usually in low densities, hindering experiments aiming to investiga

34 S cones had an inverse topography with very low densities in the central retina and highest densitie

35 owing to an unexpectedly high proportion of low-density infection among symptomatic subjects.

36 ation assay to provide estimates of both the low-density intrinsic growth rate, lambda, and the carry

37 application of ligandless UA-IL-DLLME using low-density ionic liquid and organic solvents for precon

38 The major obstacle to persistence at low density is successful fertilisation (union between e

39 its vibronic structure, is duplicated in the low-density limit.

40 a (FH) is characterized by severely elevated low density lipoprotein (LDL) cholesterol.

41 contributes to atherosclerosis by targeting low density lipoprotein (LDL) receptor (LDLR) degradatio

42 show that alpha2delta-1 is a ligand for the Low Density Lipoprotein (LDL) Receptor-related Protein-1

43 kinetics of key biological proteins, namely Low Density Lipoprotein (LDL), Tissue Necrosis Factor al

44 Egg yolk low density lipoprotein (LDL)/polysaccharide nanogels ar

45 is tempers triglyceride availabiity for very low density lipoprotein assembly and allows homeostatic

46 the CC-genotype was associated with elevated low density lipoprotein cholesterol (LDLc) and total cho

47 n signals via the lipoprotein receptors very low density lipoprotein receptor (VLDLR) and apolipoprot

48 t mice (0.162 cm(2)+/-0.023 [n=9], P2X7(-/-) low density lipoprotein receptor(-/-) : 0.084 cm(2)+/-0.

49 xpression was analyzed in aortic arches from low density lipoprotein receptor(-/-) mice consuming a h

50 P2X7(+/+) and P2X7(-/-) low density lipoprotein receptor(-/-) mice were fed a hi

51 Low density lipoprotein receptor-null (Ldlr(-/-)) mice o

52 ent increases mRNA and protein expression of low density lipoprotein receptor-related protein 2 and a

53 ent and activation of beta1 integrin via the low density lipoprotein receptor-related protein-1 (LRP1

54 There was a significant reduction in low density lipoprotein-cholesterol (LDL-C), an increase

55 Plasma levels of total cholesterol (T-CHL), low density lipoprotein-cholesterol (LDL-CHL), and resis

56 and cardiovascular disease (CVD) context and low density lipoprotein-cholesterol concentrations withi

57 ces, -0.35 kg/m(2); 95% CI, -0.62 to -0.07), low-density lipoprotein (4 studies; mean differences, -0

58 Uptake of labeled low-density lipoprotein (LDL) and cholesterol was measur

59 95% CI, 0.80-0.95, per mmol/l increase), and low-density lipoprotein (LDL) cholesterol (OR, 0.83; 95%

60 btilisin/kexin type 9 (PCSK9), lowers plasma low-density lipoprotein (LDL) cholesterol and apolipopro

61 e cardiometabolic risk-factor profile [lower low-density lipoprotein (LDL) cholesterol and triglyceri

62 e subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by appr

63 was found to produce sustained reductions in low-density lipoprotein (LDL) cholesterol levels over th

64 despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels.

65 oncern that these drugs or the low levels of low-density lipoprotein (LDL) cholesterol that result fr

66 l3 mRNA, Angptl3 protein, triglycerides, and low-density lipoprotein (LDL) cholesterol, as well as re

67 mes were: blood pressure, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density

68 nstrated to be associated with at least 1 of low-density lipoprotein (LDL) cholesterol, high-density

69 type 9 (PCSK9), a target for the lowering of low-density lipoprotein (LDL) cholesterol.

70 n-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol.

71 isin-kexin type 9 (PCSK9), reduces levels of low-density lipoprotein (LDL) cholesterol.

72 Incubation of plasma electronegative low-density lipoprotein (LDL) from UNx rats with normal

73 Electronegative low-density lipoprotein (LDL) has been shown to increase

74 Although sequence analysis of low-density lipoprotein (LDL) receptor (LDLR) mRNA did n

75 To this end, the low-density lipoprotein (LDL) receptor was targeted for

76 isin/kexin type 9 (PCSK9) down-regulates the low-density lipoprotein (LDL) receptor, elevating LDL ch

77 iosynthesis thereby upregulating the hepatic low-density lipoprotein (LDL) receptors and increasing t

78 ther the most electronegative subfraction of low-density lipoprotein (LDL), L5, is correlated with QT

79 Low-density lipoprotein (LDL), one of the four major gro

80 9 (PCSK9), such as evolocumab, lower plasma low-density lipoprotein (LDL)-cholesterol concentrations

81 CDP) on the role of non-statin therapies for low-density lipoprotein (LDL)-cholesterol lowering in th

82 terol (MD -8.5 mg/dl, 95% CI -9.5, -7.4) and low-density lipoprotein (MD -2.4 mg/dl, 95% CI -3.4, -1.

83 d leads to the uptake of native and oxidized low-density lipoprotein (oxLDL) by macrophages (Mvarphis

84 Oxidized low-density lipoprotein (oxLDL) is known to activate inf

85 CD36 recognizes oxidized lipids in oxidized low-density lipoprotein (oxLDL) particles, a process tha

86 Retained oxidized low-density lipoprotein (oxLDL), in turn, stimulated myo

87 that internalize lipids, including oxidized low-density lipoprotein (oxLDL).

88 notion that HCV coopts the secretion of very-low-density lipoprotein (VLDL) for its egress.

89 impaired ER-to-Golgi trafficking of pre-very low-density lipoprotein (VLDL) particles.

90 tic triglycerides (TAG) associated with very-low-density lipoprotein (VLDL) play a major role in main

91 ) for 8 weeks on the plasma kinetics of very-low-density lipoprotein (VLDL)-apolipoprotein B-100 (apo

92 d proteomic profiles implicated these 3 very-low-density lipoprotein (VLDL)-associated apolipoprotein

93 ortant for HCV cell-to-cell spread, but very-low-density lipoprotein (VLDL)-containing mouse serum di

94 erved strong positive associations with very-low-density lipoprotein (VLDL)-lipoproteins, VLDL-choles

95 blood pressure 51.2%; body mass index 33.8%; low-density lipoprotein 31.4%; and waist-to-hip ratio 29

96 preventing inflammation induced by oxidized low-density lipoprotein and promoting apoptotic cell cle

97 ss 6 to 12 months, including blood pressure, low-density lipoprotein and total cholesterol levels, an

98 tween noncoding rare variants in SLC22A3 and low-density lipoprotein and total cholesterol, associati

99 h a third who had residual cholesterol risk (Low-density lipoprotein cholesterol >100 mg/dL).

100 Children with HeFH (age, 6-<18 years) and low-density lipoprotein cholesterol >4.9 mmol/L or >4.1

101 ntion parameters-aspirin use, lipid control (low-density lipoprotein cholesterol <70 mg/dL or statin

102 ncomitant therapies, including patients with low-density lipoprotein cholesterol <70 mg/dl.

103 idence interval, 18-27; P<1.0x10(-4)), lower low-density lipoprotein cholesterol (-12.2 mg/dL; 95% co

104 ipoprotein cholesterol (1.6 [1.2-2.2]), high low-density lipoprotein cholesterol (1.6 [1.1-2.1]), and

105 ]), obesity (3.7 [2.0-7.0]), borderline high low-density lipoprotein cholesterol (1.6 [1.2-2.2]), hig

106 63.1%), LDL cholesterol (1.3 to 32.9%), very-low-density lipoprotein cholesterol (27.9 to 60.0%), non

107 oach using only childhood lipid measures for low-density lipoprotein cholesterol (area under the rece

108 Pravastatin lowered low-density lipoprotein cholesterol (change in SD units

109 t showed differential responses in total and low-density lipoprotein cholesterol (decreased in LFHC g

110 For low-density lipoprotein cholesterol (LDL) of 130-159 mg/

111 Patients with primary elevations of low-density lipoprotein cholesterol (LDL-C) >/=190 mg/dL

112 se <126 mg/dl, total cholesterol <240 mg/dl, low-density lipoprotein cholesterol (LDL-C) <160 mg/dl,

113 iglycerides (TGs), high-density (HDL-C), and low-density lipoprotein cholesterol (LDL-C) (n=627).

114 ma concentrations of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and apolipop

115 Serum low-density lipoprotein cholesterol (LDL-C) and high-den

116 Increased serum levels of low-density lipoprotein cholesterol (LDL-C) are an indep

117 oring nonfasting lipid assessment may affect low-density lipoprotein cholesterol (LDL-C) estimation.

118 elected individuals with increased levels of low-density lipoprotein cholesterol (LDL-C) have shown m

119 tients with elevated 10-year risk (>5%) or a low-density lipoprotein cholesterol (LDL-C) level of 4.9

120 noclonal antibody against PCSK9 that reduces low-density lipoprotein cholesterol (LDL-C) levels by 55

121 itors in patients with persistently elevated low-density lipoprotein cholesterol (LDL-C) levels despi

122 ter transfer protein (CETP) inhibitors lower low-density lipoprotein cholesterol (LDL-C) levels witho

123 amination of the effects of lifetime reduced low-density lipoprotein cholesterol (LDL-C) on cardiovas

124 Low-density lipoprotein cholesterol (LDL-C) reductions w

125 exin type 9 monoclonal antibodies can reduce low-density lipoprotein cholesterol (LDL-C) to very low

126 vestigated whether the relative reduction in low-density lipoprotein cholesterol (LDL-c) was a good i

127 igh-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyc

128 Elevated cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), is frequent

129 preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C).

130 key role in regulating the levels of plasma low-density lipoprotein cholesterol (LDL-C).

131 imarily expressed in the liver and regulates low-density lipoprotein cholesterol (LDL-C).

132 one of the scavenger receptors for oxidized low-density lipoprotein cholesterol (ox-LDL), plays a cr

133 patients after acute coronary syndrome with low-density lipoprotein cholesterol 50 to 125 mg/dL were

134 igh-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], total chole

135 e subtilisin/kexin type 9), markedly reduces low-density lipoprotein cholesterol across diverse patie

136 n/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular e

137 me-wide significant variants associated with low-density lipoprotein cholesterol and coronary heart d

138 creased body mass index, active smoking, and low-density lipoprotein cholesterol and lipoprotein(a) l

139 nsistent relationship between lower achieved low-density lipoprotein cholesterol and lower risk of li

140 s and cumulative exposure to lower levels of low-density lipoprotein cholesterol are not associated w

141 atment to placebo in individuals with normal low-density lipoprotein cholesterol but increased C-reac

142 sult in lifelong exposure to lower levels of low-density lipoprotein cholesterol can provide informat

143 ificantly lower median time-weighted average low-density lipoprotein cholesterol compared with placeb

144 t-day humans, including variants involved in low-density lipoprotein cholesterol concentrations, schi

145 s in the face of lower levels of circulating low-density lipoprotein cholesterol in mice lacking miR-

146 A1c was -0.022 +/- 0.53%; however, total and low-density lipoprotein cholesterol increased significan

147 CI, -0.82 to -0.16]; 23 trials [n = 58022]), low-density lipoprotein cholesterol level (-2.58 mg/dL [

148 , but approval rates did not vary by patient low-density lipoprotein cholesterol level nor statin use

149 ter publication) in the cohort with elevated low-density lipoprotein cholesterol levels (ie, >/=190 m

150 , including reductions in blood pressure and low-density lipoprotein cholesterol levels and improveme

151 atherosclerotic cardiovascular disease with low-density lipoprotein cholesterol levels of at least 7

152 counted net price of $10311 in patients with low-density lipoprotein cholesterol levels of at least 8

153 Individuals with elevated fasting low-density lipoprotein cholesterol levels were also ran

154 Higher low-density lipoprotein cholesterol levels were not asso

155 sment of the efficacy and safety of lowering low-density lipoprotein cholesterol levels with atorvast

156 iagnoses, lipid-lowering medication use, and low-density lipoprotein cholesterol levels.

157 24% (95% CI, 8-37; P=0.004) despite similar low-density lipoprotein cholesterol lowering.

158 on the potential long-term effects of lower low-density lipoprotein cholesterol on neurocognitive im

159 of early initiation of statin treatment for low-density lipoprotein cholesterol reduction in childre

160 eye examination, hemoglobin A1c testing, and low-density lipoprotein cholesterol testing), prescribin

161 sed on benefits estimated from reductions in low-density lipoprotein cholesterol that occurred in PCS

162 Low-fat diets tend to improve low-density lipoprotein cholesterol the most, while lowe

163 The median admission low-density lipoprotein cholesterol was lower among pati

164 s coronary intervention, and higher level of low-density lipoprotein cholesterol were independent pre

165 Moreover, lowering of low-density lipoprotein cholesterol with evolocumab redu

166 Low-density lipoprotein cholesterol(LDL-C) is a well est

167 (A), biomarkers (B) (NT-proBNP, hs-cTnT, and low-density lipoprotein cholesterol), and clinical varia

168 -8 mg/dl for total cholesterol, -8 mg/dl for low-density lipoprotein cholesterol, +8 mg/dl for remnan

169 ed on 58 single-nucleotide polymorphisms for low-density lipoprotein cholesterol, 71 single-nucleotid

170 nt of saturated with unsaturated fats lowers low-density lipoprotein cholesterol, a cause of atherosc

171 ype natriuretic peptide, and lower levels of low-density lipoprotein cholesterol, adiponectin, lipopr

172 with progressively higher levels of glucose, low-density lipoprotein cholesterol, and blood pressure.

173 ntrol subjects and had higher triglycerides, low-density lipoprotein cholesterol, and HbA1c and lower

174 pe 9 (PCSK9) inhibitors substantially reduce low-density lipoprotein cholesterol, but it is presently

175 nic profile scores for BMI, HDL cholesterol, low-density lipoprotein cholesterol, coronary artery dis

176 ng insulin, triglyceride, total cholesterol, low-density lipoprotein cholesterol, fasting glucose, di

177 high-density lipoprotein cholesterol, lower low-density lipoprotein cholesterol, lower triglycerides

178 Current smoking, low-density lipoprotein cholesterol, multivessel CAD, di

179 In multivariable analysis, older age, higher low-density lipoprotein cholesterol, pack per year of sm

180 Also, total cholesterol, low-density lipoprotein cholesterol, triacylglycerol, gl

181 Application of SCOPA to two GWAS of high-and low-density lipoprotein cholesterol, triglycerides and b

182 1 microbe intervention in rats reduced serum low-density lipoprotein cholesterol, triglycerides and t

183 ex, fasting plasma glucose, glycohemoglobin, low-density lipoprotein cholesterol, triglycerides, high

184 ensitivity cardiac troponin T (hs-cTnT), and low-density lipoprotein cholesterol, where NT-proBNP and

185 is-methylation quantitative trait loci for a low-density lipoprotein cholesterol-related differential

186 that includes potent statin therapy and low low-density lipoprotein cholesterol.

187 n, blood pressure, albuminuria, smoking, and low-density lipoprotein cholesterol.

188 ulating triglycerides and a 12% reduction in low-density lipoprotein cholesterol.

189 ent-specific ratios of triglycerides to very low-density lipoprotein cholesterol.

190 lycerols, apolipoproteins A-I and B, or very low-density lipoprotein cholesterol.

191 ed back into the cellular media, whereas the low-density lipoprotein component was localized to the l

192 Exposure of macrophages to oxidized low-density lipoprotein downregulated LKB1 in vitro.

193 Even after accounting for baseline low-density lipoprotein level, statin exposure continued

194 ffect persists after accounting for baseline low-density lipoprotein level.

195 (-250.19 g; 95% CI, -459.9 to -40.5 g), and low-density lipoprotein levels (-15.4 mg/dL; 95% CI, -23

196 n-1(Sort1), a known regulator of circulating low-density lipoprotein levels in humans, as a novel tar

197 After accounting for baseline low-density lipoprotein levels, persons who filled presc

198 gh-density lipoprotein lipids and lower very-low-density lipoprotein lipids, glucose levels, branched

199 % confidence interval 3.48-6.78), other very-low-density lipoprotein measures, and branched-chain ami

200 inhibition of PCSK9 has any effects on very low-density lipoprotein or intermediate-density lipoprot

201 xidative stress were measured in plasma: (1) low-density lipoprotein oxidizability, (2) high-density

202 Low-density lipoprotein oxidizability, indicative of the

203 macrophage LKB1 reduction caused by oxidized low-density lipoprotein promotes foam cell formation and

204 icantly improved high-density lipoprotein to low-density lipoprotein ratios in high fat-fed mice with

205 Female low-density lipoprotein receptor (Ldlr) deficient mice w

206 audin-1 (CLDN1), Occludin (OCLN), SR-BI, and low-density lipoprotein receptor (LDLR), function mainly

207 ertase subtilisin/kexin type 9 (PCSK9) binds low-density lipoprotein receptor (LDLR), preventing its

208 As proof-of-principle, we targeted the low-density lipoprotein receptor (Ldlr), which when dele

209 the inflamed aorta in atherosclerosis-prone low-density lipoprotein receptor deficient (Ldlr(-/-)) m

210 element binding protein 2 and downregulating low-density lipoprotein receptor expression.

211 METHODS AND Paradoxically, Ldlr(-/-) (low-density lipoprotein receptor null) mice deficient in

212 clerotic lesion size was found in Ldlr(-/-) (low-density lipoprotein receptor null) mice transplanted

213 ion disrupts an interaction with VLDLR (very low-density lipoprotein receptor), while the APOER2 sign

214 arrow-restricted deletion of DNGR-1 in Ldlr (low-density lipoprotein receptor)-deficient mice (Ldlr(-

215 teraction with the RELN receptor VLDLR (very low-density lipoprotein receptor); this was confirmed by

216 Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), one of the s

217 Tet2-mutant cells in atherosclerosis-prone, low-density lipoprotein receptor-deficient (Ldlr(-/-)) m

218 od vessels invading photoreceptors: the very low-density lipoprotein receptor-deficient (Vldlr(-/-) )

219 In a low-density lipoprotein receptor-deficient atherosclerot

220 results in decreased hepatic inflammation in low-density lipoprotein receptor-deficient mice on a Wes

221 ress as prime response pathways in livers of low-density lipoprotein receptor-deficient mice on a Wes

222 Low-density lipoprotein receptor-related protein 1 (LRP-

223 Low-density lipoprotein receptor-related protein 1 (LRP1

224 , the receptors for these secreted proteins, low-density lipoprotein receptor-related protein 1 (LRP1

225 ction with the endocytic scavenger receptor, low-density lipoprotein receptor-related protein 1 (LRP1

226 ancer have identified novel functions of the low-density lipoprotein receptor-related protein 4-muscl

227 ptions of tryptophan hydroxylase 1 (Tph1) or low-density lipoprotein receptor-related protein 5 (Lrp5

228 rocytic thrombospondin-1 (TSP1) and synaptic low-density lipoprotein receptor-related protein-1 (LRP1

229 Low-density lipoprotein receptor-related protein-1 (LRP1

230 (LPS) by a pathway that apparently requires low-density lipoprotein receptor-related protein-1 (LRP1

231 rocytic thrombospondin-1 (TSP1) and synaptic low-density lipoprotein receptor-related protein-1 (LRP1

232 receptors frizzled 1-10 and the co-receptors low-density lipoprotein receptor-related proteins 5 and

233 ntiplatelet therapy, blood pressure control, low-density lipoprotein reduction, and lifestyle modific

234 Blocking hepatic very low-density lipoprotein secretion through genetic or pha

235 echanisms and consequences of defective very low-density lipoprotein secretion.

236 links to the apolipoprotein B component of a low-density lipoprotein through a disulfide bridge to fo

237 rporation into palmitate of circulating very low-density lipoprotein triglyceride.

238 tions were observed for extremely large very-low-density lipoprotein triglycerides (odds ratio [OR] =

239 sion of SRA (scavenger receptor A), modified low-density lipoprotein uptake and foam cell formation,

240 isease who require further reduction in LDL (low-density lipoprotein) and non-HDL-C.

241 Exposure of monocytes to oxidized low-density lipoprotein, 7-ketocholesterol, phorbol 12-m

242 biomarkers, namely, fibrinogen, adiponectin, low-density lipoprotein, and 8-isoprostane.

243 ciated with a significant increase in total, low-density lipoprotein, and high-density lipoprotein (H

244 Serum levels of total cholesterol (TC), TG, low-density lipoprotein, and high-density lipoprotein we

245 resulted in significant reductions in total, low-density lipoprotein, and non-high-density lipoprotei

246 lasma levels of very low-density lipoprotein/low-density lipoprotein, high-density lipoprotein, trigl

247 tein component, indicating their origin from low-density lipoprotein, intermediate-density lipoprotei

248 tein, intermediate-density lipoprotein, very-low-density lipoprotein, lipoprotein (a), or chylomicron

249 IHD, systolic and diastolic blood pressure, low-density lipoprotein- and total cholesterol, triglyce

250 xcept for an inverse association of FT4 with low-density lipoprotein-cholesterol.

251 n DCs on atherosclerosis were examined using low-density lipoprotein-deficient (Ldlr(-/-)) bone marro

252 RATIONALE: Lipoprotein(a) [Lp(a)] is a low-density lipoprotein-like lipoprotein and important c

253 ystemic treatment with anti-inflammatory and low-density lipoprotein-lowering drugs are currently bei

254 that triglyceride levels causally influence low-density lipoprotein.

255 No changes in plasma levels of very low-density lipoprotein/low-density lipoprotein, high-de

256 rin Efficacy International Trial by reducing low-density-lipoprotein (LDL) cholesterol levels more th

257 igh-density-lipoprotein cholesterol (HDL-C), low-density-lipoprotein cholesterol (LDL-C), and/or trig

258 In parallel, the low-density-lipoprotein receptor plays a predominant rol

259 ticularly in the cholesterol content of very-low-density lipoproteinparticles.

260 Although EC are in constant contact with low density lipoproteins (LDL), how EC process LDL and w

261 with cholesterol concentrations in high- and low-density lipoproteins (HDL and LDL) particles measure

262 lied with cholesterol derived from uptake of low-density lipoproteins (LDL) and synthesis.

263 Low-density lipoproteins (LDLs) are a class of nanocarri

264 hages ingest high levels of damaged modified low-density lipoproteins (LDLs), generating macrophage f

265 induced by cholesterol crystals and oxidized low-density lipoproteins (ox-LDL), potentially by increa

266 Very-low-density lipoproteins (VLDL) is a hallmark of metabol

267 very low-density lipoproteins-apoB and very low-density lipoproteins triglycerides or on postprandia

268 tivity and total HDL antioxidant capacity on low-density lipoproteins), and HDL vasodilatory capacity

269 ocumab had no effects on FCRs or PRs of very low-density lipoproteins-apoB and very low-density lipop

270 pond to the glassy states of high- (HDL) and low-density liquid (LDL) in the metastable part of the p

271 they would be in a high-density gas or in a low-density liquid phase.

272 The resulting low-density mechanical metamaterials have many advantage

273 f CD33, PMN-MDSCs were identified as CD33(+) low-density neutrophils.

274 At low densities, NPCs moved randomly in an amoeba-like fas

275 However, introducing low densities of a highly specific piscivorous fish into

276 liver into the blood, being associated with low densities of asexual parasites and the absence of ga

277 cal resonance, despite the low viscosity and low density of air.

278 mosomal breakpoints appear in the regions of low density of conserved noncoding elements (CNEs) and t

279 A relatively low density of defects was observed.

280 use plantar paw skin is also innervated by a low density of Mrgprd(+) nociceptors, while individual a

281 tion that the marsupial isocortex contains a low density of neurons, we found that neuron numbers per

282 igh spatial acuity for noxious stimuli but a low density of pain-sensing neurites.

283 eads harbor a high density of pepA-beta2aHC, low density of pepF-beta2aHC, and are lacking beta2fHC.

284 n of many clays on Mars, and the anomalously low density of the Martian crust in comparison with expe

285 ne and in situ pre-equilibrium sampling with low density polyethylene (LDPE) loaded with performance

286 e also created a unique opportunity to study low-density population dynamics and quantify Allee effec

287 ion models, we found potential for explosive low-density population growth (lambda > 5) and complex d

288 In simulated populations, low-density populations had a stronger indication of IBD

289 that function can be derived from expanded, low density protein states has broad implications for ou

290 from materials of high elastic stiffness and low density, represent some of the lightest, stiffest an

291 c IDPs can phase separate to form permeable, low-density (semi-dilute) liquids, whose structural feat

292 Low-density stroma and high lymphocyte levels showed inc

293 e of a high density, "fragile" liquid, and a low density, "strong" liquid, the varying proportion of

294 ctures, large spherical granules, and small, low-density structures.

295 eration stemming from large-scale gradients, low-density targets, irradiated by an intense near-infra

296 The polyamorphic transformation from low density to high density with a transition region bet

297 of both the glass transition and the high-to-low-density transition are debated and new experimental

298 and dynamical properties during the high-to-low-density transition in amorphous ice at 1 bar.

299 to act as long-distance pollinators of many low-density tropical plants.

300 valence form stable, volume-spanning gels at low density, whereas central regions with higher average